Nuvation Bio (NUVB) CMO exercises options and sells 50,000 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Nuvation Bio Inc. chief medical officer Dongfang Liu reported an exercise-and-sell transaction in Class A common stock. Liu exercised stock options to acquire 50,000 shares at $1.94 per share, then sold 50,000 shares in open-market trades at a weighted-average price of $5.02 per share.
The sales, executed at prices ranging from $5.00 to $5.07, were made under a pre-arranged Rule 10b5-1 trading plan dated December 4, 2025. After these transactions, Liu holds 18,000 shares of Class A common stock and 430,000 stock options expiring on February 27, 2033.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 50,000 shares ($251,000)
Net Sell
3 txns
Insider
Liu Dongfang
Role
CHIEF MEDICAL OFFICER
Sold
50,000 shs ($251K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 50,000 | $0.00 | -- |
| Exercise | Class A Common Stock | 50,000 | $1.94 | $97K |
| Sale | Class A Common Stock | 50,000 | $5.02 | $251K |
Holdings After Transaction:
Stock Option (Right to Buy) — 430,000 shares (Direct, null);
Class A Common Stock — 68,000 shares (Direct, null)
Footnotes (1)
- Shares sold pursuant to a 10b5-1 plan dated December 4, 2025. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $5.00 to $5.07. The Reporting Person will provide, upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Option vests as to 25% on February 28, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date
Key Figures
Shares sold: 50,000 shares
Sale price: $5.02 per share
Options exercised: 50,000 shares
+4 more
7 metrics
Shares sold
50,000 shares
Class A common stock sold in open market on April 17, 2026
Sale price
$5.02 per share
Weighted-average sale price; trades ranged $5.00–$5.07
Options exercised
50,000 shares
Options exercised into Class A common stock on April 17, 2026
Option exercise price
$1.94 per share
Strike price for exercised stock options
Shares held after
18,000 shares
Direct Class A common stock holdings after transactions
Options remaining
430,000 options
Stock options outstanding after exercise, expiring February 27, 2033
Net share change
50,000 shares
Net-sell shares according to transaction summary
Key Terms
Rule 10b5-1 plan, weighted-average sales price, Stock Option (Right to Buy), vesting, +1 more
5 terms
Rule 10b5-1 plan regulatory
"Shares sold pursuant to a 10b5-1 plan dated December 4, 2025."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted-average sales price financial
"Price reported is a weighted-average sales price."
Stock Option (Right to Buy) financial
"Security title listed as Stock Option (Right to Buy)."
vesting financial
"Option vests as to 25% on February 28, 2024, and monthly thereafter."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
derivative security financial
"Exercise or conversion of derivative security."
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
What insider transaction did Nuvation Bio (NUVB) report for Dongfang Liu?
Nuvation Bio reported that chief medical officer Dongfang Liu exercised options for 50,000 Class A shares at $1.94 and sold 50,000 shares in open-market trades at a weighted-average price of $5.02, as disclosed in the Form 4 insider filing.
Was the NUVB insider sale by Dongfang Liu under a 10b5-1 plan?
Yes. The filing states that Dongfang Liu’s 50,000-share sale was executed pursuant to a Rule 10b5-1 trading plan dated December 4, 2025. Such pre-arranged plans automate trading and can reduce the significance of transaction timing for interpreting insider sentiment.
What stock options does NUVB’s Dongfang Liu retain after exercising 50,000 options?
After exercising 50,000 options, Liu still holds 430,000 stock options with a $1.94 exercise price. A footnote explains these options vest 25% on February 28, 2024, then monthly over 36 months, and they are scheduled to expire on February 27, 2033.